Article citationsMore>>
Blesa, R., Bullock, R., He, Y., Bergman, H., Gambina, G., Meyer, J., Rapatz, G., Nagel, J. and Lane, R. (2006) Effect of Butyrylcholinesterase Genotype on the Response to Rivastigmine or Donepezil in Younger Patients with Alzheimer’s Disease. Pharmacogenetics and Genomics, 16, 771-774.
http://dx.doi.org/10.1097/01.fpc.0000220573.05714.ac
has been cited by the following article:
-
TITLE:
Prevalence of Wild-Type Butyrylcholinesterase Genotype in Patients with Alzheimer’s Dementia
AUTHORS:
Beate Mueller, Georg Adler
KEYWORDS:
Butyrylcholinesterase, Alzheimer’s Disease, Genotype
JOURNAL NAME:
World Journal of Neuroscience,
Vol.5 No.3,
June
2,
2015
ABSTRACT: Approximately, two-thirds patients
with Alzheimer’s disease (AD) are reported to have homozygous wild-type
butyrylcholinesterase (BuChE) gene expression. It is associated with a higher
rate of hydrolysis of acetylcholine, which ultimately leads to increase in the
levels of BuChE in advanced stages of the disease. Rivastigmine, a dual
inhibitor of acetylcholinesterase (AChE) and BuChE, might be of additional
benefit in patients with AD with wild-type BuChE allele.
Related Articles:
-
Mahendra Dia, Todd C. Wehner, Consuelo Arellano
-
Govindappa Gopalakrishna, Mohamed Shareef, Poorigali Chowdaiah Nagesh
-
Hadidjatou Bélem, Roland Nâg-Tiero Meda, Benjamin Kouliga Koama, Windmi Kagambéga, Sandrine Nadege Da, Anne Flora Drabo, Assetou Sawadogo, Cyprial Ndumiso Ncobela, Marie-Pierre Létourneau-Montminy, Amadou Traoré, George Anicet Ouédraogo
-
Gumpeny Ramachandra Sridhar, Talluri Sekhar, Padmanabhuni Venkata Nageswara Rao, Allam Appa Rao
-
Xiting Chen